WuXi Biologics' revenue grew 18.4% in the first half of 2026, with the total number of projects reaching 1,064.
WuXi Biologics submitted its first-half 2026 results report to the Hong Kong Stock Exchange on August 25. For the six months ended June 30, net profit attributable to shareholders increased 4.3% to RMB 2.44 billion, while revenue increased 18.4% to RMB 11.79 billion. During the period, 169 new integrated projects were added, bringing the total to 1,064. First-Half 2026 Revenue and Gross Margin For the six months ended June 30, 2026, WuXi Biologics’ revenue increased 18.4% to RMB 11.79 billion, w
Bisc·08-26 02:31

